Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Acute Leukoencephalopathies:Differential Diagnosis and Investigation
The Neurologist 4:148-166, Weinshenker,B.G.,et al, 1998
A 34-Year-Old Man with Headache, Diploplia, and Hemiparesis
Neurol 86:e28, Lincoln, M.R.,et al, 2016
The Etiology of Ring Lesions on Diffusion-Weighted Imaging
NeuroRadiol J 27:280-287, Finelli, P. & Foxman, E.B., 2014
Rhombencephalitis A Series of 97 Patients
Medicine 90:256-261, Moragas, M.,et al, 2011
Internuclear Ophthalmoplegia
Arch Neurol 62:714-717, Keane,J.R., 2005
Lesions of the Corpus Callosum: MR Imaging and Differential Considerations in Adults and Children
AJR 179:251-257, Bourekas,E.C.,et al, 2002
Isolated Cranial Nerve Palsies Due to Brainstem Lesions
Muscle & Nerve 22:1168-1176, Thomke,F., 1999
Ocular Torsion and Tilt of Subjective Visual Vertical are Sensitive Brainstem Signs
Ann Neurol 33:292-299, Dieterich,M.&Brandt,T., 1993
Clinical Presentations of Vascular Malformations of the Brain Stem:Comparison of Angiographically Positive and Negative Types
JNNP 52:167-175, Abe,M.,et al, 1989
Divisional Oculomotor Nerve Paresis Caused by Intrinsic Brainstem Disease
Ann Neurol 26:714-718, Ksiazek,S.M.,et al, 1989
The One- & -A-Half Syndrome-A Unilateral Disorder of the Pontine Tegmentum:A Study of 20 Cases & Review of the Liter
Neurol 33:971-980, Wall,M.,et al, 1983
The Clinical & Pathological Spectrum of Brainstem Vascular Malformations
Arch Neurol 37:25-29, Stahl,S.M.,et al, 1980
Clinical Correlations of Periodic Lateralized Epileptiform Discharges
Clin Electroenceph 8:191-202, Porecha,H.P.&Reilly,E.L., 1977
Bilateral Sixth Nerve Palsy
Arch Neurol 33:681, Keane,J.R., 1976
The Geography of Neurology
BMJ 2:506, Spillane,J.D., 1972
Brain Stem Arteriovenous Malformations
Arch Ophthalmol 86:255, Lessel,S.,et al, 1971
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Progressive Multifocal Leukoencephalopathy in a Patient with Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy
JAMA Neurol 78:736-740, Patel,A.,et al, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Radiologically Isolated Syndrome: A Review for Neuroradiologists
AJNR 41:1542-1549, Hosseiny, M.,et al, 2020
Multiple Sclerosis
NEJM 378:169-180, Reich, D.S.,et al, 2018
Progressive multifocal leukoencephalpathy after fingolimod treatment
Neurol 90:1815-e1821, Berger, J.R.,et al, 2018
Misdiagnosis of Multiple Sclerosis
Neurol 92:15-16, Brownlee, W.J., 2018
Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017
Dentate Update: Imaging Features of Entities that Affect the Dentate Nucleus
AJNR 38:1467-1474, Bond, K.M.,et al, 2017
The Useless Hand of Oppenheim
Pract Neurol 17:464-468, Wiblin, L. & Guadagno, J., 2017
Cardiovascular Dysfunction in Multiple Sclerosis
Neurologist 20:108-114, Kaplan, T.B.,et al, 2015
Solitary Sclerosis
Neurol 78:540-544, Schmalstieg,W.F.,et al, 2012
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
NEJM 366:1870-1880,1938, Bloomgren, G.,et al, 2012
Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
Neurol 77:1061-1067,1033, Tan, I.L.,et al, 2011
Management and Outcome of CSF-JC Virus PCR-negative PML in a Natalizumab-treated Patient with MS
Neurol 77:2010-2016, Kuhle, J.,et al, 2011
Diffusely Abnormal White Matter in Progressive Multiple Sclerosis: In Vivo Quantitative MR Imaging Characterization and Comparison between Disease Types
AJNR 31:541-548, 390, Vrenken,H.,et al, 2010
Natalizumab and Progressive Multifocal Leukoencephalopathy: What are the Causal Factors and Can It be Avoided?
Arch Neurol 67:923-930, Warnke,C., et al, 2010
JC Virus Infection of the Brain
AJNR 31:1564-1576, Bag,A.K.,et al, 2010
Progressive Multifocal Leukoencephalopathy: Can We Reduce Risk in Patients Receiving Biological Immunomodulatory Therapies?
Ann Neurol 68:271-274, Tyler,K., 2010
Brainstem Lesion in Clinically Isolated Syndromes
Neurol 75:1933-1938, Tintore,M.,et al, 2010
Successful Management of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy and Immune Reconstitution Syndrome in a Patient With Multiple Sclerosis
Arch Neurol 67:1391-1394, Schr�der,A.,et al, 2010
Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009
Clinicopath Conf, Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL)
NEJM 360:1656-1665, Case 12-2009, 2009
Diffusely Abnormal White Matter in Chronic Multiple Sclerosis: Imaging and Histopathologic Analysis
Arch Neurol 66:601-609, Seewann,A.,et al, 2009
Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis: A Comparative Study
Arch Neurol 66:593-599, Boster,A.,et al, 2009
Progressive Multifocal Leukoencephalopathy After Natalizumab Monotherapy
NEJM 361:1081-1087, Linda,H.,et al, 2009
Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
NEJM 361:1075-1080, Wenning,W.,et al, 2009
Reemergence of PML in Natalizumab-Treated Patients--New Cases, Same Concerns
NEJM 361:1041-1043, Major,E., 2009
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
Assessment: The Use of Natalizumab (Tysabri) for the Treatment of Multiple Sclerosis (An Evidence-Based Review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 71:766-773, Goodin,D.S.,et al., 2008
Reactivation of JC Virus and Development of PML in Patients With Multiple Sclerosis
Neurol 68:985-990, Khalili,K.,et al, 2007
Quantifying the Risks and Benefits of Natalizumab in Relapsing Multiple Sclerosis
Neurol 68:1524-1528, Dorsey,E.R.,et al, 2007